Pfizer cancer drug trial halted early after only 9 patients

NCT ID NCT06285097

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 29 times

Summary

This early-stage study tested a new experimental drug (PF-07820435) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, skin, and kidney cancers. The goal was to check safety and find the right dose. Only 9 people took part before the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Corewell Health (reference non-engagement letter)

    Grand Rapids, Michigan, 49503, United States

  • Florida Cancer Specialists Sarasota Drug Development Unit

    Sarasota, Florida, 34232, United States

  • Hospital Oncologico Dr. Isaac Gonzalez-Martinez

    Rio Piedras, 00935, Puerto Rico

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • Pan American Center for Oncology Trials, LLC

    Rio Piedras, 00935, Puerto Rico

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee, 37203, United States

  • The Cancer Institute Hospital of JFCR

    Koto, Tokyo, 135-8550, Japan

  • Tristar Centennial Medical Center

    Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.